Cargando…

Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation

Certain immunophenotypes in multiple myeloma (MM), including CD56 and CD117, have been reported to be associated with overall survival (OS). However, previous reports have ignored the impact of different treatment regimens and the long-term prognostic value of immunophenotyping in MM when treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huan, Zhou, Xin, Zhu, Jian-Wei, Ye, Jian-Nan, Guo, Hong-Feng, Sun, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176261/ https://www.ncbi.nlm.nih.gov/pubmed/30344721 http://dx.doi.org/10.3892/ol.2018.9365

Ejemplares similares

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia
por: Raeisi, Mortaza, et al.
Publicado: (2019)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
por: Chim, Chor Sang
Publicado: (2010)

The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma
por: Popek-Marciniec, Sylwia, et al.
Publicado: (2023)

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
por: Kiba, Takayoshi, et al.
Publicado: (2014)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

ATM/RB1 mutations predict shorter overall survival in urothelial cancer
por: Yin, Ming, et al.
Publicado: (2018)

GDF11 upregulation independently predicts shorter overall-survival of uveal melanoma
por: Liu, Xun, et al.
Publicado: (2019)

Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
por: Onken, Julia, et al.
Publicado: (2017)

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy
por: Narita, T, et al.
Publicado: (2015)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
por: Sonneveld, Pieter, et al.
Publicado: (2023)

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
por: Sonneveld, P, et al.
Publicado: (2022)

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2020)

Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5
por: Carlsten, Mattias, et al.
Publicado: (2018)

LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype
por: Anwar, Sumadi Lukman, et al.
Publicado: (2019)

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
por: Prince, H Miles, et al.
Publicado: (2007)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series
por: MAO, JINGJUE, et al.
Publicado: (2014)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia
por: Gimenes-Teixeira, Hamilton L, et al.
Publicado: (2013)

Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma
por: He, Xia, et al.
Publicado: (2019)

Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases
por: van Dijk, David P.J., et al.
Publicado: (2021)

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
por: Vangsted, Annette J, et al.
Publicado: (2010)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2mquj6tcvq3f7bpa0bij0hngsa